356 related articles for article (PubMed ID: 9393982)
1. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
Clark J; Lu YJ; Sidhar SK; Parker C; Gill S; Smedley D; Hamoudi R; Linehan WM; Shipley J; Cooper CS
Oncogene; 1997 Oct; 15(18):2233-9. PubMed ID: 9393982
[TBL] [Abstract][Full Text] [Related]
2. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
[TBL] [Abstract][Full Text] [Related]
3. Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.
Heimann P; El Housni H; Ogur G; Weterman MA; Petty EM; Vassart G
Cancer Res; 2001 May; 61(10):4130-5. PubMed ID: 11358836
[TBL] [Abstract][Full Text] [Related]
4. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
6. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
[TBL] [Abstract][Full Text] [Related]
7. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.
Mathur M; Samuels HH
Oncogene; 2007 Jan; 26(2):277-83. PubMed ID: 16832349
[TBL] [Abstract][Full Text] [Related]
8. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
[TBL] [Abstract][Full Text] [Related]
9. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.
Chang IW; Huang HY; Sung MT
Am J Surg Pathol; 2009 Dec; 33(12):1894-901. PubMed ID: 19809274
[TBL] [Abstract][Full Text] [Related]
10. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.
Mathur M; Das S; Samuels HH
Oncogene; 2003 Aug; 22(32):5031-44. PubMed ID: 12902986
[TBL] [Abstract][Full Text] [Related]
11. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).
Argani P; Lui MY; Couturier J; Bouvier R; Fournet JC; Ladanyi M
Oncogene; 2003 Aug; 22(34):5374-8. PubMed ID: 12917640
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
13. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
14. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
[TBL] [Abstract][Full Text] [Related]
15. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene.
Sidhar SK; Clark J; Gill S; Hamoudi R; Crew AJ; Gwilliam R; Ross M; Linehan WM; Birdsall S; Shipley J; Cooper CS
Hum Mol Genet; 1996 Sep; 5(9):1333-8. PubMed ID: 8872474
[TBL] [Abstract][Full Text] [Related]
16. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
[TBL] [Abstract][Full Text] [Related]
17. Secondary PSF/TFE3-associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma.
Brassesco MS; Valera ET; Bonilha TA; Scrideli CA; Carvalho de Oliveira J; Pezuk JA; Barros Silva GE; Costa RS; Tone LG
Cancer Genet; 2011 Feb; 204(2):108-10. PubMed ID: 21504709
[TBL] [Abstract][Full Text] [Related]
18. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
19. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
[TBL] [Abstract][Full Text] [Related]
20. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
